dc.contributor.advisor | Alam, Marzia | |
dc.contributor.author | Afsana, Nourin | |
dc.date.accessioned | 2022-09-11T04:19:59Z | |
dc.date.available | 2022-09-11T04:19:59Z | |
dc.date.copyright | 2021 | |
dc.date.issued | 2021-09 | |
dc.identifier.other | ID 16346053 | |
dc.identifier.uri | http://hdl.handle.net/10361/17186 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021. | en_US |
dc.description | Cataloged from PDF version of thesis report. | |
dc.description | Includes bibliographical references (pages 31-46). | |
dc.description.abstract | One of the most remarkable health problems we have faced since the World War II is the COVID-19 outbreak. This review article discusses insights from basic science as well as clinical perspectives on COVID-19 disease with a specific concern on Parkinson’s disease (PD). Patients with COVID-19 have compromised immunity, especially in an aged population suffering from PD. The 1st report on the relationship between COVID-19 and PD comes from the research on antibodies against four antigens of COVID-19 in Cerebrospinal Fluid (CSF) of normal controls compared to patients with neurological illnesses, especially PD. Unfortunately, identification of COVID-19 is difficult in PD patients because PD is often preceded by anosmia, which is a common feature of COVID-19. Presently, no disease-modifying treatment is available for PD. But for temporary relief, the treatment is composed of dopaminergic drugs like levodopa and PD patients with COVID-19 are treated with favipiravir, amantadine etc. where amantadine was the first FDA-approved medicine in the United States that indicates dual function in the treatment of both diseases. This review also discusses the COVID-19 negative impact on PD patients due to lockdown/isolation. To conclude, this review is mainly focused on the COVID-19 and PD relationship, consequences of PD patients infected with COVID-19, treatment options and COVID-19 impact on PD patients. | en_US |
dc.description.statementofresponsibility | Nourin Afsana | |
dc.format.extent | 46 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Covid-19 | en_US |
dc.subject | Parkinson's disease | en_US |
dc.subject | Antibodies | en_US |
dc.subject | Anosmia | en_US |
dc.subject | Amantadine | en_US |
dc.subject | Lockdown | en_US |
dc.subject.lcsh | Parkinson's disease | |
dc.subject.lcsh | COVID-19 (Disease)--Treatment | |
dc.title | Parkinson’s disease and COVID-19: treatment and patient management during a pandemic | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | Department of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |